We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+14.35%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.65B
AUM Growth
+$205M
Cap. Flow
-$69.3M
Cap. Flow %
-2.62%
Top 10 Hldgs %
39.13%
Holding
181
New
13
Increased
25
Reduced
35
Closed
9

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$17.1M
2
PFE icon
Pfizer
PFE
+$15.6M
3
BIIB icon
Biogen
BIIB
+$14.1M
4
MCK icon
McKesson
MCK
+$12.2M
5
AVTR icon
Avantor
AVTR
+$9.51M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M
2
JNJ icon
Johnson & Johnson
JNJ
+$24.9M
3
HUM icon
Humana
HUM
+$18.5M
4
AZN icon
AstraZeneca
AZN
+$15.7M
5
MOH icon
Molina Healthcare
MOH
+$15.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.55%
2 Real Estate 1.68%
3 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
1
UnitedHealth
UNH
$383B
$143M 5.42%
270,546
-3,500
-1% -$1.85M
AMGN icon
2
Amgen
AMGN
$209B
$134M 5.05%
508,676
-10,193
-2% -$2.73M
GILD icon
3
Gilead Sciences
GILD
$163B
$130M 4.9%
1,510,440
-111,725
-7% -$8.85M
JNJ icon
4
Johnson & Johnson
JNJ
$617B
$113M 4.27%
639,679
-144,100
-18% -$24.9M
LLY icon
5
Eli Lilly
LLY
$1.03T
$106M 3.99%
288,917
+48,339
+20% +$17.1M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$122B
$95.4M 3.6%
330,343
+16,940
+5% +$5.16M
REGN icon
7
Regeneron Pharmaceuticals
REGN
$77.4B
$87.2M 3.29%
120,862
+11,800
+11% +$8.71M
ABBV icon
8
AbbVie
ABBV
$455B
$77.3M 2.92%
478,342
-48,500
-9% -$7.44M
ABT icon
9
Abbott
ABT
$183B
$76.1M 2.87%
693,051
-98,000
-12% -$10.1M
PFE icon
10
Pfizer
PFE
$142B
$74.7M 2.82%
1,457,170
+325,067
+29% +$15.6M
AZN icon
11
AstraZeneca
AZN
$266B
$69.3M 2.62%
511,128
-125,469
-20% -$15.7M
ILMN icon
12
Illumina
ILMN
$31B
$64.7M 2.44%
328,917
+25,716
+8% +$5.33M
MRK icon
13
Merck
MRK
$321B
$61.3M 2.31%
552,122
– –
CI icon
14
Cigna
CI
$76.1B
$60.5M 2.29%
182,631
-28,100
-13% -$8.89M
BIIB icon
15
Biogen
BIIB
$30.7B
$54.1M 2.04%
195,430
+49,991
+34% +$14.1M
TMO icon
16
Thermo Fisher Scientific
TMO
$214B
$51.6M 1.95%
93,705
– –
BMY icon
17
Bristol-Myers Squibb
BMY
$132B
$49.5M 1.87%
687,529
-191,947
-22% -$14.5M
MRNA icon
18
Moderna
MRNA
$23B
$47.6M 1.8%
264,927
-49,997
-16% -$8.17M
HZNP
19
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$47.2M 1.78%
415,053
-319,300
-43% -$26.5M
SYK icon
20
Stryker
SYK
$133B
$40.1M 1.52%
164,128
-29,400
-15% -$6.67M
HUM icon
21
Humana
HUM
$44B
$39.8M 1.5%
77,713
-35,291
-31% -$18.5M
BSX icon
22
Boston Scientific
BSX
$68.4B
$35M 1.32%
757,015
-38,200
-5% -$1.65M
ALNY icon
23
Alnylam Pharmaceuticals
ALNY
$27.4B
$34M 1.29%
143,214
– –
ZBH icon
24
Zimmer Biomet
ZBH
$18.4B
$33M 1.25%
258,868
– –
UTHR icon
25
United Therapeutics
UTHR
$26.2B
$32M 1.21%
115,077
-2,300
-2% -$581K
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Tekla Capital Management held 181 positions worth $2.65B, up 8.4% from $2.44B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q4 2022 filing shows 13 new, 25 increased, 35 reduced and 9 closed positions. Its largest new stake was Avantor: 459,488 shares worth $9.69M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q4 2022 buy was Avantor: 459,488 shares worth $9.69M.
  • Tekla Capital Management added most to Eli Lilly in Q4 2022, an estimated $17.1M increase.
  • Tekla Capital Management's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $26.5M.
  • Tekla Capital Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $10.6M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.65B portfolio in Q4 2022.
  • Tekla Capital Management opened 13 new positions and closed 9 in Q4 2022.
  • Tekla Capital Management's portfolio value rose 8.4% quarter-over-quarter to $2.65B.

Based on Tekla Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.